Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL‐24 gene in liver cancer cells

Wang, Chunming; Li, Qiang; Xiao, Boduan; Fang, Huiling; Huang, Biao; Huang, Fang; Wang, Yigang

doi:10.1002/jcla.23677

Cited by 15 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver cancer is the world's third largest cause of cancer mortality [ 65 ]. The burden and aetiology of liver diseases have changed during the last decade [ 66 , 67 ]. In this respect, Cao et al (2018) showed that luteolin reduces the SMMC-7721 cell viability in a time- and dose-dependent fashion.…”

Section: Anticancer Properties Of Luteolin and Its Mechanism Of Actionmentioning

confidence: 99%

Revisiting luteolin: An updated review on its anticancer potential

Rauf,

Wilairatana,

Joshi

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Anticancer Properties Of Luteolin and Its Mechanism Of Actionmentioning

confidence: 99%

Revisiting luteolin: An updated review on its anticancer potential

Rauf,

Wilairatana,

Joshi

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Cancer-targeting gene-viro therapy (CTGVT), which uses oncolytic viral vectors that encode anticancer genes, has been shown to have potent anticancer activities [ 113 ]. In a study by Wang et al, 2021, the researchers used oncolytic vaccinia virus (VV) that encoded the IL-24 gene (VV-IL-24) as the model for CTVGT in the treatment of liver cancer and investigated the potential synergistic effect of Luteolin to the treatment [ 114 ]. The study revealed that the combination of VV-IL-24 and Luteolin caused a stronger decrement in the viability and induction of apoptosis of liver cancer cells compared to Luteolin or VV-IL-24 alone.…”

Section: Anticancer Properties Of Luteolin On Different Cancersmentioning

confidence: 99%

“…The study revealed that the combination of VV-IL-24 and Luteolin caused a stronger decrement in the viability and induction of apoptosis of liver cancer cells compared to Luteolin or VV-IL-24 alone. Additionally, in the MHCC97-H xenograft liver cancer model, combination treatment resulted in significant tumor reduction compared to a single treatment, exhibiting the synergistic mechanism employed by VV-IL-24 and Luteolin to treat liver cancer [ 114 ].…”

Section: Anticancer Properties Of Luteolin On Different Cancersmentioning

confidence: 99%

Therapeutic Potential of Luteolin on Cancer

Çetinkaya

Baran

2023

Vaccines

View full text Add to dashboard Cite

Cancer is a global concern, as the rate of incidence is increasing each year. The challenges related to the current chemotherapy drugs, such as the concerns related to toxicity, turn to cancer therapeutic research to discover alternative therapy strategies that are less toxic to normal cells. Among those studies, the use of flavonoids—natural compounds produced by plants as secondary metabolites for cancer therapy—has been a hot topic in cancer treatment. Luteolin, a flavonoid that has been present in many fruits, vegetables, and herbs, has been identified to exhibit numerous biological activities, including anti-inflammatory, antidiabetic, and anticancer properties. The anticancer property of Luteolin has been extensively researched in many cancer types and has been related to its ability to inhibit tumor growth by targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression. It achieves this by interacting with various signaling pathways and proteins. In the current review, the molecular targets of Luteolin as it exerts its anticancer properties, the combination therapy that includes Luteolin with other flavonoids or chemotherapeutic drugs, and the nanodelivery strategies for Luteolin are described for several cancer types.

show abstract

“…Due to its special molecular characteristics, endocrine therapy and molecular targeted therapy, along with other treatment approaches, have not been effective in the clinical treatment of TNBC, leading to high rates of distant recurrence and mortality (9,11,12). In recent years, researchers have focused on TNBC and other cancer treatments and have made several progress (13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

LncRNA Inhibits the Viability of Triple-Negative Breast Cancer (TNBC) by Targeting the miR-330-5p/BCL2L2 Axis

Ye,

Fan,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) play important regulatory roles in the progression of kinds of cancers. However, the biological roles of most lncRNAs in breast cancer, especially TNBC, remain unclear. In this study, we investigated the functional of a novel lncRNA, named lncRNA EWSAT1, in the breast cancer and the underlying molecular mechanisms. EWSAT1 was significantly upregulated in the triple negative breast cancer (TNBC) tissues compared with adjacent normal tissues in the GEO databases. We verified the upregulated level of EWSAT1 in the TNBC patients’ serums compared with healthy serums, which also associated with clinical diagnosis. Bioinformatics analysis demonstrated that microRNA (miR)-330-5p was a potential target of SEAS1. Dual luciferase reporter assays confirmed that EWSAT1 functioned as a sponge for miR-330-5p, regulating the expression of BCL2L2. Moreover, RT-qPCR demonstrated that EWSAT1 negatively regulated the expression of miR-330-5p, and positively regulated the expression of BCL2L2 at transcription and protein level. CCK-8 demonstrated that EWSAT1 could inhibit the viability of TNBC cells. In conclusion, our studies find a functional lncRNA EWSAT1 in the TNBC, and reveal a novel pathway for TNBC treatment via EWSAT1/miR-330-5p/BCL2L2, and suggest EWSAT1 might be a potential biomarkers for TNBC diagnosis and therapeutic target for TNBC.

show abstract

Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL‐24 gene in liver cancer cells

Cited by 15 publications

References 34 publications

Revisiting luteolin: An updated review on its anticancer potential

Revisiting luteolin: An updated review on its anticancer potential

Therapeutic Potential of Luteolin on Cancer

LncRNA Inhibits the Viability of Triple-Negative Breast Cancer (TNBC) by Targeting the miR-330-5p/BCL2L2 Axis

Contact Info

Product

Resources

About